Clinical trials: neoadjuvant therapy, completed
Rectal Cancer
Exercise Training in Colorectal Cancer Patients
Neoadjuvant chemoradiotherapy (NACRT) prior to surgery for lower gastrointestinal (colon and rectal) cancer is associated with improved survival, but also adversely affects physical fitness, potentially rendering patients unfit…
- Trial name
- NCT01325909
- Testing
- Exercise programme
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Michelle Mossa
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Breast Diseases
Long Term Use of SAVI SCOUT: Pilot Study
The purpose of this study is to evaluate the performance of FDA-cleared SAVI SCOUT Breast Localization and Surgical Guidance System (SCOUT) over a longer duration prior to surgery.
- Trial name
- NCT03015649
- Testing
- SAVI SCOUT Surgical Guidance System
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Envision Healthcare Scientific Intelligence, Inc.
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
The goal of this clinical research study is to learn if giving Iressa (Gefitinib or ZD1839) with surgery and/or radiation will help to control squamous cell carcinoma of the skin. The safety of this treatment will also be studied
- Trial name
- NCT00126555
- Testing
- Gefitinib, Radiotherapy, Conventional surgery
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
- Trial name
- ADAPT (NCT01781338)
- Testing
- Induction therapy
- Where
- 2 sites in Germany
- Volunteers
- 4,936 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy
The primary goals of this trial will be to determine the safety and immune activity of HER-2 pulsed DC1 vaccine in patients with high risk HER-2pos breast cancer with residual disease post neoadjuvant therapy.
- Trial name
- Neoadjuvant (NCT02061423)
- Testing
- HER-2 pulsed Dendritic Cell Vaccine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Esophageal Neoplasms
Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial
The purpose of this study is to compare the results of preoperative chemotherapy and radiation followed by surgery to surgery followed by postoperative chemotherapy and radiation for esophageal cancer.
- Trial name
- QUINTETT (NCT00907543)
- Testing
- Preoperative treatment of chemotherapy and radiation, Postoperative treatment of chemotherapy and radiation
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- Richard Malthaner
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
Phase II trial of Neoadjuvant [FEC100]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer
- Trial name
- NCT00535509
- Testing
- Cisplatin-Docetaxel ± Trastuzumab
- Volunteers
- 285 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Rheumatoid Arthritis
Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)
This is a prospective, open-label, 1-arm, multicenter observational study to determine the average Remicade dosage and time span between 9 infusions in subjects with rheumatoid arthritis (RA)
- Trial name
- NCT00725621
- Testing
- Infliximab
- Volunteers
- 516 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer treated with cytarabine in the laboratory may help doctors learn more about the effects of cytarabine on cells.
- Trial name
- NCT01338974
- Testing
- gene expression analysis, proteomic profiling, flow cytometry
- Volunteers
- 290 people
- Sponsor
- SWOG Cancer Research Network
Melanoma
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
This study plans to to estimate the safety profile of the combination biotherapy regimen consisting of standard-dose interferon alpha-2b (HDI) and anti-PD1 monoclonal antibody, Pembrolizumab, for the neoadjuvant therapy of…
- Trial name
- NCT02339324
- Testing
- Pembrolizumab and high dose interferon alfa-2b (HDI)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Yana Najjar
Rectal Cancer
Relationship Between Lymph Node Ratio and Survival Rate in Preoperative Chemoradiation Rectal Cancer Patients
Colorectal cancer is the most-common cancer of the gastrointestinal tract. The number of positive lymph nodes and total number of lymph nodes retrieved are important prognostic factors.
- Trial name
- NCT04096118
- Where
- Thailand
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00003593
- Testing
- asparaginase, cytarabine, daunorubicin hydrochloride
- Where
- 237 sites in United States, Australia and 5 more
- Volunteers
- 254 people
- Sponsor
- Children's Oncology Group
Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
The aim is to determine the recommended phase 2 dose (RP2D) of binimetinib in combination with pemetrexed and cisplatin, and to demonstrate that the combination is feasible and has preliminary activity in previously untreated…
- Conditions
- Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation, Lung Cancer
- Trial name
- NCT02964689
- Testing
- Binimetinib, Pemetrexed, Cisplatin
- Where
- 4 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- Swiss Cancer Institute
Breast Neoplasms
Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy
In estrogen receptor (ER)-positive breast cancer (BC), human epidermal growth factor receptor-2 (HER2)-low ones are reported to have distinct clinical and molecular features from those with HER2-zero or HER2-positive status.
- Trial name
- NCT05673850
- Testing
- NET or NCT
- Where
- China
- Volunteers
- 518 people
- Sponsor
- Peking University
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
This randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT01293032
- Testing
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Virginia Commonwealth University
Leukemia, Myeloid, Acute
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive…
- Trial name
- NCT01721876
- Testing
- Volasertib, Cytarabine
- Where
- 122 sites in United States, Argentina and 23 more
- Volunteers
- 666 people
- Sponsor
- Boehringer Ingelheim
Human Papilloma Virus, Squamous Cell Carcinoma
De-Escalation Therapy for Human Papillomavirus Negative Disease
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the…
- Conditions
- Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma
- Trial name
- DEPEND (NCT03944915)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.